Previous 10 | Next 10 |
home / stock / dskyf / dskyf news
Summary FDA and EU approved, the joint therapy Enhertu is set to become a blockbuster. The therapy targets HER-2 cancers and is already expanding indications beyond breast cancer. With this successful antibody-drug conjugate, the entire sub-industry is now seeing renewed momentum he...
Japanese pharmaceutical giant Daiichi Sankyo ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) on Wednesday said Europe's drug regulator had validated a change to its application for lung cancer treatment Enhertu. The European Medicines Agency (EMA) validated a Type II variation application for Enhertu...
Summary VPL's portfolio is highly diversified, invests significantly in sectors with high growth potential, has a low expense ratio, and is trading at a marginal discount. Though VPL's current yield is not excessively high, it seems to be sustainable and the fund generates a high enough...
Kite Pharma, a Gilead Company ( NASDAQ: GILD ), and Daiichi Sankyo Co., Ltd. ( OTCPK:DSNKY ) jointly announced the revision of their 2017 partnership pact , which gave Daiichi Sankyo exclusive rights to develop, manufacture and commercialize Yescarta in Japan. Kite was ac...
Daiichi Sankyo ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) said its mRNA-based COVID-19 vaccine DS-5670 met the main goal in a booster vaccination trial. The Japanese company said the booster vaccination trial included ~5K Japanese healthy adult and elderly people who had compl...
An expert panel of the European Medicines Agency (EMA) has recommended issuing marketing authorization for Daiichi Sankyo ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) to include gastric cancer as an indication for Enhertu, an antibody-drug conjugate the company develops with AstraZeneca ( ...
Daiichi Sankyo Company, Limited (DSKYF) Q2 2022 Results Conference Call October 31, 2022 01:30 AM ET Company Participants Sunao Manabe - Representative Director, President and CEO Wataru Takasaki - Head, R&D Division Hiroyuki Okuzawa - Head, Corporate Plannin...
Summary Global growth stocks held up better than value, snapping a two-quarter losing streak, as global recession fears weighed more heavily on companies tied to the broader economy. The Strategy outperformed for the second quarter in a row, thanks in large part to positioning adj...
Daiichi Sankyo Co. press release ( OTCPK:DSKYF ): 1H GAAP EPS of ¥30.39. Revenue of ¥607.79B (+14.7% Y/Y). For further details see: Daiichi Sankyo Co. GAAP EPS of ¥30.39, revenue of ¥607.79B
Summary The Strategy outperformed for the second quarter in a row, thanks in large part to positioning adjustments made over the last year in preparation for these extreme macro headwinds. We enhanced a focus on sturdy, secular growth businesses with three new additions to the portfol...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Company Name:
DSKYF Stock Symbol:
OTCMKTS Market:
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...